INMUNOCAT study : The impact of molecular diagnosis on immunotherapy prescription in pollen polysensitized patients from Catalonia
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology..
BACKGROUND: Recognition of specific allergens triggering immune response is key for the appropriate prescription of allergen-specific immunotherapy (SIT). This study aimed at evaluating the impact of using the commercially available microarray ImmunoCAPTM ISAC 112 (Thermo Fisher Scientific) on the etiological diagnosis and SIT prescription compared to the conventional diagnostic methods in patients with allergic rhinitis/rhinoconjunctivitis and/or asthma.
METHODS: 300 patients with respiratory allergic disease, sensitized to three or more pollen aeroallergens from different species, as assessed by a skin prick test (SPT) and specific IgE assays (sIgE), were included in this multicentric, prospective observational study. SPT and a blood test were performed to all patients. Total serum IgE and sIgE (ImmunoCAPTM) for allergens found positive in the SPT and sIgE allergen components (ImmunoCAPTM ISAC 112) were measured.
RESULTS: According to SPT results, the most prevalent pollen sensitizers in our population were Olea europaea followed by grass, Platanus acerifolia and Parietaria judaica. The molecular diagnosis (MD) revealed Ole e 1 as the most prevalent pollen sensitizer, followed by Cup a 1, Phl p 1, Cyn d 1, Par j 2, Pla a 1, 2, and 3 and Phl p 5. Immunotherapy prescription changed, due to MD testing, in 51% of the cases, with an increase of prescription of SIT from 39% to 65%.
CONCLUSION: The identification of the allergen eliciting the respiratory disease is essential for a correct immunotherapy prescription. The advances in allergen characterization using methods, such as the commercial microarray ImmunoCAPTM ISAC 112, can help clinicians to improve SIT prescription.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical and translational allergy - 13(2023), 5 vom: 25. Mai, Seite e12246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garriga-Baraut, Teresa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asthma |
|---|
| Anmerkungen: |
Date Revised 28.05.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/clt2.12246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357297857 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357297857 | ||
| 003 | DE-627 | ||
| 005 | 20231226072259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/clt2.12246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357297857 | ||
| 035 | |a (NLM)37227418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garriga-Baraut, Teresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INMUNOCAT study |b The impact of molecular diagnosis on immunotherapy prescription in pollen polysensitized patients from Catalonia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. | ||
| 520 | |a BACKGROUND: Recognition of specific allergens triggering immune response is key for the appropriate prescription of allergen-specific immunotherapy (SIT). This study aimed at evaluating the impact of using the commercially available microarray ImmunoCAPTM ISAC 112 (Thermo Fisher Scientific) on the etiological diagnosis and SIT prescription compared to the conventional diagnostic methods in patients with allergic rhinitis/rhinoconjunctivitis and/or asthma | ||
| 520 | |a METHODS: 300 patients with respiratory allergic disease, sensitized to three or more pollen aeroallergens from different species, as assessed by a skin prick test (SPT) and specific IgE assays (sIgE), were included in this multicentric, prospective observational study. SPT and a blood test were performed to all patients. Total serum IgE and sIgE (ImmunoCAPTM) for allergens found positive in the SPT and sIgE allergen components (ImmunoCAPTM ISAC 112) were measured | ||
| 520 | |a RESULTS: According to SPT results, the most prevalent pollen sensitizers in our population were Olea europaea followed by grass, Platanus acerifolia and Parietaria judaica. The molecular diagnosis (MD) revealed Ole e 1 as the most prevalent pollen sensitizer, followed by Cup a 1, Phl p 1, Cyn d 1, Par j 2, Pla a 1, 2, and 3 and Phl p 5. Immunotherapy prescription changed, due to MD testing, in 51% of the cases, with an increase of prescription of SIT from 39% to 65% | ||
| 520 | |a CONCLUSION: The identification of the allergen eliciting the respiratory disease is essential for a correct immunotherapy prescription. The advances in allergen characterization using methods, such as the commercial microarray ImmunoCAPTM ISAC 112, can help clinicians to improve SIT prescription | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a change | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a molecular diagnosis | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a pollen polysensitized patients | |
| 650 | 4 | |a rhinitis | |
| 650 | 4 | |a rhinoconjunctivitis | |
| 700 | 1 | |a Moncín, M M San Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Tena, Mercè |e verfasserin |4 aut | |
| 700 | 1 | |a Labrador-Horrillo, Moisés |e verfasserin |4 aut | |
| 700 | 0 | |a Comitè d’Al·lèrgia Respiratòria de Catalunya, Spain |e verfasserin |4 aut | |
| 700 | 1 | |a Asensio, O |e investigator |4 oth | |
| 700 | 1 | |a Bartra, J |e investigator |4 oth | |
| 700 | 1 | |a Belmonte, J |e investigator |4 oth | |
| 700 | 1 | |a Bobolea, I |e investigator |4 oth | |
| 700 | 1 | |a De Linares, C |e investigator |4 oth | |
| 700 | 1 | |a Farrarons, L |e investigator |4 oth | |
| 700 | 1 | |a Miquel, S |e investigator |4 oth | |
| 700 | 1 | |a Muñoz-Cano, R |e investigator |4 oth | |
| 700 | 1 | |a Padró-Casas, C |e investigator |4 oth | |
| 700 | 1 | |a Pedemonte, C |e investigator |4 oth | |
| 700 | 1 | |a Raga, E |e investigator |4 oth | |
| 700 | 1 | |a Viñas, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational allergy |d 2011 |g 13(2023), 5 vom: 25. Mai, Seite e12246 |w (DE-627)NLM216124530 |x 2045-7022 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:5 |g day:25 |g month:05 |g pages:e12246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/clt2.12246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 5 |b 25 |c 05 |h e12246 | ||